## Clinical Efficacy of Phosphodiesterase-5 Inhibitor Tadal Randomized, Placebo-controlled, Double-blind Crossov

Congenital Heart Disease 6, 424-431 DOI: 10.1111/j.1747-0803.2011.00561.x

**Citation Report** 

#	Article	IF	CITATIONS
1	Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011. International Journal of Cardiology, 2011, 154, S20-S33.	1.7	46
2	What we need to know about drug interactions in patients with pulmonary arterial hypertension. Progress in Pediatric Cardiology, 2012, 34, 119-122.	0.4	1
3	Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. Current Pediatrics Reports, 2013, 1, 92-101.	4.0	2
4	Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. Clinics in Chest Medicine, 2013, 34, 707-717.	2.1	10
5	Worsening in oxygen saturation and exercise capacity predict adverse outcome in patients with Eisenmenger syndrome. International Journal of Cardiology, 2013, 168, 1386-1392.	1.7	27
6	Eisenmenger syndrome in an adult patient with a large patent ductus arteriosus. European Respiratory Review, 2013, 22, 558-564.	7.1	7
7	Impact of Sildenafil on Survival of Patients With Eisenmenger Syndrome. Journal of Clinical Pharmacology, 2013, 53, 611-618.	2.0	29
8	Comparative Effectiveness and Safety of Drug Therapy for Pulmonary Arterial Hypertension. Chest, 2014, 145, 1055-1063.	0.8	39
9	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Global Cardiology Science & Practice, 2014, 2014, 42.	0.4	12
10	Survey of the current status and management of Eisenmenger syndrome: A Japanese nationwide survey. Journal of Cardiology, 2014, 63, 286-290.	1.9	2
11	Pulmonary hypertension related to congenital heart disease: a call for action. European Heart Journal, 2014, 35, 691-700.	2.2	150
12	Pulmonary arterial hypertension associated with congenital heart disease: Recent advances and future directions. International Journal of Cardiology, 2014, 177, 340-347.	1.7	57
13	The Exceptional and Far-Flung Manifestations of Heart Failure in Eisenmenger Syndrome. Heart Failure Clinics, 2014, 10, 91-104.	2.1	18
14	Pulmonary Hypertension in Adult Congenital Heart Disease. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 328.	0.9	2
15	Pulmonary hypertension related to congenital heart disease: A comprehensive review. Global Cardiology Science & Practice, 2015, 2015, 42.	0.4	0
16	Clinical Evaluation and Management of Pulmonary Hypertension in the Adult With Congenital Heart Disease. Circulation, 2015, 131, 200-210.	1.6	40
17	Current therapy of Eisenmenger syndrome. Journal of Thoracic Disease, 2016, 8, 3009-3011.	1.4	1
18	Pulmonary Hypertension and Congenital Heart Disease. Cardiology Clinics, 2016, 34, 391-400.	2.2	25

CITATION REPORT

#	ARTICLE	IF	CITATIONS
19	Common long-term complications of adult congenital heart disease: avoid falling in a H.E.A.P Expert Review of Cardiovascular Therapy, 2016, 14, 445-462.	1.5	37
20	Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors. Sexual Medicine Reviews, 2017, 5, 170-199.	2.9	17
21	Advanced Therapy in Eisenmenger Syndrome. Cardiology in Review, 2017, 25, 126-132.	1.4	7
22	Safety and effectiveness of tadalafil in patients with pulmonary arterial hypertension: Japanese post-marketing surveillance data. Current Medical Research and Opinion, 2017, 33, 963-971.	1.9	3
24	Eisenmenger Syndrome: Pathophysiology and Haematologic Effects. Congenital Heart Disease in Adolescents and Adults, 2017, , 29-44.	0.2	0
25	Pulmonary Arterial Hypertension Complicating Congenital Heart Disease: Advances in Therapy. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 636-650.	2.1	7
26	The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease. Journal of Clinical Medicine, 2017, 6, 40.	2.4	17
27	The spectrum of pulmonary arterial hypertension in adults with congenital heart disease: management from a physician and nurse specialist perspective. Journal of Congenital Cardiology, 2017, 1, .	0.5	0
28	Pulmonary arterial hypertension in adult congenital heart disease. Heart, 2018, 104, 1568-1574.	2.9	58
29	Managing the Eisenmenger syndrome: a call to arms. Heart, 2018, 104, 714-716.	2.9	1
30	Management of Adults With Congenital Heart Disease and Pulmonary Arterial Hypertension in the UK: Survey of Current Practice, Unmet Needs and Expert Commentary. Heart Lung and Circulation, 2018, 27, 1018-1027.	0.4	7
31	Atrial septal defects and pulmonary arterial hypertension. Journal of Thoracic Disease, 2018, 10, S2953-S2965.	1.4	27
32	Pulmonary Hypertension and Eisenmenger Physiology. In Clinical Practice, 2018, , 117-141.	0.0	0
33	Pulmonary arterial hypertension in congenital heart disease. Continuing Cardiology Education, 2018, 4, 23-33.	0.4	7
34	Pulmonary Arterial Hypertension Medical Management of the Adult Patient with Congenital Heart Disease. Cardiovascular Innovations and Applications, 2018, 3, .	0.3	0
35	Heart Failure in Adults With Congenital Heart Disease. , 2018, , 331-352.		1
36	Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease. Pulmonary Circulation, 2018, 8, 1-12.	1.7	15
37	Heart Failure, Exercise Intolerance, and Physical Training. , 2018, , 77-87.		0

CITATION REPORT

#	Article	IF	CITATIONS
38	A Multifaceted Approach to Pulmonary Hypertension in Adults With Congenital Heart Disease. Progress in Cardiovascular Diseases, 2018, 61, 320-327.	3.1	6
39	Medical Therapy for Eisenmenger Syndrome: A Case Report and Review of Literature. International Journal of Angiology, 2019, 30, 305-309.	0.6	1
40	Eisenmenger syndrome and other types of pulmonary arterial hypertension related to adult congenital heart disease. Expert Review of Cardiovascular Therapy, 2019, 17, 449-459.	1.5	13
41	2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension. Journal of the Formosan Medical Association, 2019, 118, 1584-1609.	1.7	27
42	Phosphodiesterase 5 inhibitors for pulmonary hypertension. The Cochrane Library, 2019, 2019, CD012621.	2.8	70
43	Eisenmenger Syndrome: A Multisystem Disorder—Do Not Destabilize the Balanced but Fragile Physiology. Canadian Journal of Cardiology, 2019, 35, 1664-1674.	1.7	23
44	What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome. Medicine (United States), 2019, 98, e15632.	1.0	8
45	Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation, 2019, 139, 51-63.	1.6	83
46	Critical Care Management of theÂAdult with Eisenmenger Syndrome and Pulmonary Arterial Hypertension Related to Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults, 2019, , 273-297.	0.2	0
47	How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy, 2019, 17, 11-18.	1.5	12
48	Adult congenital heart disease with pulmonary arterial hypertension: mechanisms and management. Heart Failure Reviews, 2020, 25, 773-794.	3.9	4
49	A single-centre, placebo-controlled, double-blind randomised cross-over study of nebulised iloprost in patients with Eisenmenger syndrome: A pilot study. International Journal of Cardiology, 2020, 299, 131-135.	1.7	12
50	Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart, 2020, 106, 1638-1645.	2.9	39
51	Pulmonary arterial hypertension: closing the gap in congenital heart disease. Current Opinion in Pulmonary Medicine, 2020, 26, 422-428.	2.6	7
52	Congenital Heart Disease and Pulmonary Hypertension. Cardiology Clinics, 2020, 38, 445-456.	2.2	11
53	Outcome after heart–lung or lung transplantation in patients with Eisenmenger syndrome. Heart, 2020, 106, 127-132.	2.9	22
54	Congenital Heart Disease-Associated Pulmonary Hypertension. Clinics in Chest Medicine, 2021, 42, 9-18.	2.1	15
55	Efficacy and safety of pulmonary vasodilators in the patients with Eisenmenger syndrome: a metaâ€analysis of randomized controlled trials. Pulmonary Circulation, 2021, 11, 1-8.	1.7	2

CITATION REPORT

#	Article	IF	CITATIONS
56	Preventing disease progression in Eisenmenger syndrome. Expert Review of Cardiovascular Therapy, 2021, 19, 501-518.	1.5	0
57	Evaluation and Management of Pulmonary Arterial Hypertension in Congenital Heart Disease. Methodist DeBakey Cardiovascular Journal, 2021, 17, 145.	1.0	4
58	Treatment of pulmonary arterial hypertension in children. Cardiovascular Diagnosis and Therapy, 2021, 11, 1144-1159.	1.7	34
59	Selexipag for pulmonary arterial hypertension in a wide range of adult congenital heart disease. International Journal of Cardiology Congenital Heart Disease, 2021, 4, 100144.	0.4	5
60	Pulmonary arterial hypertension in adults with congenital heart disease: markers of disease severity, management of advanced heart failure and transplantation. Expert Review of Cardiovascular Therapy, 2021, 19, 837-855.	1.5	2
61	Advanced therapies in complex congenital heart disease. Journal of Congenital Cardiology, 2020, 4, .	0.5	1
62	Pulmonary Hypertension in Congenital Heart Disease. , 2014, , 2159-2199.		0
63	Eisenmenger Syndrome and Other Types of Pulmonary Arterial Hypertension Related to Congenital Heart Disease. , 2014, , 2481-2494.		4
64	Targeted Pulmonary Arterial Hypertension Therapies and a Combined Medical-Surgical Approach for Congenital Heart Disease Patients. Advances in Pulmonary Hypertension, 2013, 11, 183-188.	0.1	0
65	Pulmonary Vasodilators in Patients with Pulmonary Arterial Hypertension Related to Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults, 2017, , 253-266.	0.2	1
66	Pulmonary Arterial Hypertension. Congenital Heart Disease in Adolescents and Adults, 2018, , 129-142.	0.2	0
67	Advanced therapies in Eisenmenger syndrome. Journal of Congenital Cardiology, 2020, 4, .	0.5	0
68	Strategies for the management of pulmonary arterial hypertension in patients with congenital heart disease. Journal of Congenital Cardiology, 2020, 4, .	0.5	5
69	Advanced therapies in pulmonary arterial hypertension and congenital heart disease in people with Down syndrome. Journal of Congenital Cardiology, 2020, 4, .	0.5	1
70	Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics. Minerva Pediatrica, 2015, 67, 169-85.	2.7	6
71	The use of pulmonary arterial hypertension therapies in Eisenmenger syndrome. Expert Review of Cardiovascular Therapy, 2021, 19, 1053-1061.	1.5	2
72	Eisenmenger Syndrome. Journal of the American College of Cardiology, 2022, 79, 1183-1198.	2.8	19
73	Targeted Therapies in Patients with Pulmonary Arterial Hypertension Due to Congenital Heart Disease. Current Vascular Pharmacology, 2022, 20, 341-360.	1.7	0

		CITATION REPORT		
#	Article		IF	CITATIONS
74	Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CH systematic review and network meta-analysis. Cardiology in the Young, 2023, 33, 229		0.8	0
75	Cessation of pulmonary vasodilators in PAH related to congenital heart disease. Journa College of Cardiology, 2023, 13, 40.	l of Indian	0.1	0
76	Cardiac Drugs in ACHD Cardiovascular Medicine. Journal of Cardiovascular Developme 2023, 10, 190.	nt and Disease,	1.6	0
77	Pulmonary Hypertension in Congenital Heart Disease: A Scientific Statement From the Association. Circulation: Heart Failure, 2023, 16, .	American Heart	3.9	9
78	Pulmonary Hypertension in Adults with Congenital Heart Disease. , 2023, , 1-50.			0
79	Pulmonary arterial hypertension in congenital heart disease. Heart, 0, , heartjnl-2023-3	22890.	2.9	0
80	Current Management and Future Directions for Pulmonary Arterial Hypertension Assoc Congenital Heart Disease. Journal of Personalized Medicine, 2024, 14, 5.	siated with	2.5	0
81	Eisenmenger Syndrome and Other Types of Pulmonary Arterial Hypertension Related t Heart Disease. , 2024, , 1-17.	o Congenital		0
82	Pulmonary Hypertension in Adult Congenital Heart Disease–Related Heart Failure. H Clinics, 2024, 20, 209-221.	eart Failure	2.1	0